Research Article
Gene Therapy (2005) 12, 579–587. doi:10.1038/sj.gt.3302441 Published online 13 January 2005
PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile
M A Croyle1,2, H T Le1, K D Linse2, V Cerullo3,4, G Toietta5, A Beaudet5 and L Pastore3,4
- 1College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, Austin, TX, USA
- 2The Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX, USA
- 3Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples 'Federico II'
- 4CEINGE-Biotecnologie Avanzate, Napoli, Italy
- 5Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
Correspondence: Dr MA Croyle, College of Pharmacy, Division of Pharmaceutics, The University of Texas at Austin, PHR 4.214D, 1 University Station #A1920, 2409 W. University Avenue, Austin, TX 78712, USA
Received 22 July 2004; Accepted 4 October 2004; Published online 13 January 2005.
Abstract
Transgene expression from helper-dependent adenoviral (HD-Ad) vectors is effective and long lasting, but not permanent. Their use is also limited by the host response against capsid proteins that precludes successful gene expression upon readministration. In this report, we test the hypothesis that PEGylation of HD-Ad reduces its toxicity and promotes transgene expression upon readministration. PEGylation did not compromise transduction efficiency in vitro and in vivo and reduced peak serum IL-6 levels two-fold. IL-12 and TNF-
levels were reduced three- and seven-fold, respectively. Thrombocytopenia was not detected in mice treated with the PEGylated vector. Serum transaminases were not significantly elevated in mice treated with either vector. Mice immunized with 1
1011 particles of unmodified HD-Ad expressing human alpha-1 antitrypsin (hA1AT) were rechallenged 28 days later with 8
1010 particles of unmodified or PEG-conjugated vector expressing beta-galactosidase. Trace levels of beta-galactosidase (52.23
19.2 pg/mg protein) were detected in liver homogenates of mice that received two doses of unmodified HD-Ad. Mice rechallenged with PEGylated HD-Ad produced significant levels of beta-galactosidase (5.1
0.4
105 pg/mg protein, P=0.0001). This suggests that PEGylation of HD-Ad vectors may be appropriate for their safe and efficient use in the clinic.
Keywords:
helper-dependent adenoviral vectors, PEGylation, toxicology, readministration, immune response
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors
Gene Therapy Review
RESEARCH
Molecular Therapy Original Article
Generation of Helper-Dependent Adenoviral Vectors by Homologous Recombination
Molecular Therapy Original Article
Readministration of helper-dependent adenovirus to mouse lung
Gene Therapy Original Article
Molecular Therapy Original Article
